Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib.

NCT03514901 is registered in ClinicalTrials.gov with Intergruppo Melanoma Italiano as lead sponsor.

NCT NCT03514901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03514901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib.
Lead sponsor
Intergruppo Melanoma Italiano
Phase
Phase 2
Overall status
Unknown status
Start date
June 18, 2018
Completion date
April 29, 2023
Enrollment
120 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, melanoma metastatic